Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide

Molecular Immunology

Volumn 48, Issue 1-3, 2010, Pages 59-72

  Robert, Remy ^a   Lefranc, Marie Paule ^b,c   Ghochikyan, Anahit ^d   Agadjanyan, Michael G ^d,e   Cribbs, David H ^e,f   Van Nostrand, William E ^g   Wark, Kim L ^a   Dolezal, Olan ^a  

^a CSIRO   (Australia)

^b UNIVERSITÉ PARIS EST   (France)

^c INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^d INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g STONY BROOK UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Anti A antibodies; Antibody engineering; Passive immunotherapy; Restricted antibody epertoire; Surface plasmon resonance

Indexed keywords

AMYLOID BETA PROTEIN; EPITOPE; IMMUNOGLOBULIN CLASS; MONOCLONAL ANTIBODY; OLIGOMER;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BIOTINYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNIZATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE; VARIABLE HEAVY CHAIN VARIABLE LIGHT CHAIN PAIRING;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; BASE SEQUENCE; COMPLEMENTARITY DETERMINING REGIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNITY, HUMORAL; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE;

MUS MUSCULUS;

EID: 78649512319     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.09.012     Document Type: Article

References (56)

1. Acton, P., An, Z., Bett, A.J., Breese, R., Chang, L., Dodson, E.C., Kinney, G., Klein, W., Lambert, M.P., Liang, X., Shughrue, P., Strohl, W.R., Viola, K. US Patent No. US 20060228349.
2. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T., Cribbs D.H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 2005, 174:1580-1586.
3. Agadjanyan M.G., Cribbs D.H. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I. CNS Neurol. Disord. Drug Targets 2009, 8:1-6.
4. Andersen P.S., Haahr-Hansen M., Coljee V.W., Hinnerfeldt F.R., Varming K., Bregenholt S., Haurum J.S. Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen. Mol. Immunol. 2007, 44:412-422.
5. Arimon M., Díez-Pérez I., Kogan M.J., Durany N., Giralt E., Sanz F., Fernàndez-Busquets X. Fine structure study of Abeta1-42 fibrillogenesis with atomic force microscopy. FASEB J. 2005, 10:1344-1346.
6. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
7. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2023-2028.
8. Basi G.S., Feinberg H., Oshidari F., Anderson J., Barbour R., Baker J., Comery T.A., Diep L., Gill D., Johnson-Wood K., Goel A., Grantcharova K., Lee M., Li J., Partridge A., Griswold-Prenner I., Piot N., Walker D., Widom A., Pangalos M.N., Seubert P., Jacobsen J.S., Schenk D., Weis W.I. Structural correlates of antibodies associated with acute reversal of A-beta related behavioral deficits in a mouse model of Alzheimer's disease. J. Biol. Chem. 2010, 285:3417-3427.
9. Bravman T., Bronner V., Lavie K., Notcovich A., Papalia G.A., Myszka D.G. Exploring " one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal. Biochem. 2006, 358:281-288.
10. Brochet X., Lefranc M.-P., Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucl. Acids Res. 2008, 36:W503-W508.
11. Caine J., Volitakis I., Cherny R., Varghese J., Macreadie I. Abeta produced as a fusion to maltose binding protein can be readily purified and stably associates with copper and zinc. Protein Pept. Lett. 2007, 14:83-86.
12. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P., Finch C.E., Krafft G.A., Klein W.L. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003, 42:12749-12760.
13. Collis A.V., Brouwer A.P., Martin A.C. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J. Mol. Biol. 2003, 325:337-354.
14. Diaw L., Siwarski D., Coleman A., Kim J., Jones G.M., Dighiero G., Huppi K. Restricted immunoglobulin variable region (IgV) gene expression accompanies secondary rearrangements of light chain IgV genes in mouse plasmacytomas. J. Exp. Med. 1999, 190:1405-1416.
15. Ehrenmann F., Kaas Q., Lefranc M.-P. IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF. Nucl. Acids Res. 2010, 38:D301-D307.
16. Fernández-Sánchez A., García-Ocaña M., de los Toyos J.R. Mouse monoclonal antibodies to pneumococcal C-polysaccharide backbone show restricted usage of VH-DH-JH gene segments and share the same kappa chain. Immunol. Lett. 2009, 123:125-131.
17. Frenkel D., Balass M., Katchalski-Katzir E., Solomon B. High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. J. Neuroimmunol. 1999, 95:136-142.
18. Frenkel D., Katz O., Solomon B. Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11455-11459.
19. Gardberg A.S., Dice L.T., Ou S., Rich R.L., Helmbrecht E., Ko J., Wetzel R., Myszka D.G., Patterson P.H., Dealwis C. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15659-15664.
20. Gellerfors, P., Lannfelt, L., Sehlin, D., Ekholm Pettersson, F., Englund, H. US Patent No. US 2009/0258009 A1.
21. Golde, T.E., Das, P., Jansen-west, K.R., Levites, Y.R. US Patent No. US20100104577.
22. Hougs L., Juul L., Svejgaard A., Barington T. Structural requirements of the major protective antibody to Haemophilus influenzae type b. Infect. Immun. 1999, 67:2503-2514.
23. Jang H., Arce F.T., Ramachandran S., Capone R., Azimova R., Kagan B.L., Nussinov R., Lal R. Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6538-6543.
24. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
25. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
26. Kleanthous C., Hemmings A.M., Moore G.R., James R. Immunity proteins and their specificity for endonuclease colicins: telling right from wrong in protein-protein recognition. Mol. Microbiol. 1998, 2:227-233.
27. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
28. Lambert M.P., Velasco P.T., Chang L., Viola K.L., Fernandez S., Lacor P.N., Khuon D., Gong Y., Bigio E.H., Shaw P., De Felice F.G., Krafft G.A., Klein W.L. Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem. 2007, 100:23-35.
29. Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S.G., Black R.S., Schenk D., Seubert P. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol. 2005, 58:430-435.
30. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., Lee V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 2006, 281:4292-4299.
31. Lefranc M.-P., Pommié C., Ruiz M., Giudicelli V., Foulquier E., Truong L., Thouvenin-Contet V., Lefranc G. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev. Comp. Immunol. 2003, 27:55-77.
32. ®. Nucl. Acids Res. 2009, 37:D1006-D1012.
33. Lemere C.A., Beierschmitt A., Iglesias M., Spooner E.T., Bloom J.K., Leverone J.F., Zheng J.B., Seabrook T.J., Louard D., Li D., Selkoe D.J., Palmour R.M., Ervin F.R. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 2004, 165:283-297.
34. McLean G.R., Olsen O.A., Watt I.N., Rathanaswami P., Leslie K.B., Babcook J.S., Schrader J.W. Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response. J. Immunol. 2005, 174:4768-4778.
35. Medecigo M., Manoutcharian K., Vasilevko V., Govezensky T., Munguia M.E., Becerril B., Luz-Madrigal A., Vaca L., Cribbs D.H., Gevorkian G. Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries. J. Neuroimmunol. 2010, 223:104-114.
36. Meli G., Visintin M., Cannistraci I., Cattaneo A. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J. Mol. Biol. 2009, 387:584-606.
37. Miles L.A., Wun K.S., Crespi G.A.N., Fodero-Tavoletti M.T., Galatis D., Bagley C.J., Beyreuther K., Masters C.L., Cappai R., McKinstry W.J., Barnham K.J., Parker M.W. Amyloid-β-anti-amyloid-β complex structure reveals an extended conformation in the immunodominant B-cell epitope. J. Mol. Biol. 2008, 377:181-192.
38. Miller D.L., Currie J.R., Mehta P.D., Potempska A., Hwang Y.W., Wegiel J. Humoral immune response to fibrillar beta-amyloid peptide. Biochemistry 2003, 42:11682-11692.
39. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003, 61:46-54.
40. Persson H., Flicker S., Sadegh M.K., Greiff L., Valenta R., Ohlin M. A common idiotype in IgE and its relation to recognition of the grass pollen allergen Phl p 2. Mol. Immunol. 2008, 45:2715-2720.
41. Pike C.J., Overman M.J., Cotman C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem. 1995, 270:23895-23898.
42. Robert R., Dolezal O., Waddington L., Hattarki M.K., Cappai R., Masters C.L., Hudson P.J., Wark K.L. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Eng. Des. Sel. 2009, 22:199-208.
43. Robert R., Streltsov V.A., Newman J., Pearce L.A., Wark K.L., Dolezal O. Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment. Protein Sci. 2010, 19:299-308.
44. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
45. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999, 399:A23-A31.
46. Shen, W., Biere-Citron, A.L. US Patent No. US2008/0292639 A1.
47. Solomon B., Koppel R., Hanan E., Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:452-455.
48. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4109-4112.
49. Thomson C.A., Bryson S., McLean G.R., Creagh A.L., Pai E.F., Schrader J.W. Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J. 2008, 27:2592-2602.
50. Vasilevko V., Pop V., Kim H.J., Saing T., Glabe C.C., Milton S., Barrett E.G., Cotman C.W., Cribbs D.H., Head E. Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis. 2010, 39:301-310.
51. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
52. Whitelegg N.R., Rees A.R. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng. 2000, 13:819-824.
53. Wilcock D.M., Alamed J., Gottschall P.E., Grimm J., Rosenthal A., Pons J., Ronan V., Symmonds K., Gordon M.N., Morgan D. Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci. 2006, 26:5340-5346.
54. Yousfi Monod M., Giudicelli V., Chaume D., Lefranc M.P. IMGT/junction analysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics 2004, 20(Suppl. 1):i379-i385.
55. Zameer A., Kasturirangan S., Emadi S., Nimmagadda S.V., Sierks M.R. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J. Mol. Biol. 2008, 384:917-928.
56. Zhang M., Zharikova D., Mozdzanowska K., Otvos L., Gerhard W. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus. Mol. Immunol. 2006, 43:2195-2206.